COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS) Files An 8-K Results of Operations and Financial Condition

Item2.02

On May8, 2017, Coherus BioSciences, Inc. issued a press release
regarding its financial results for its first quarter ended
March31, 2017. The full text of the press release is furnished as
Exhibit 99.1 to this Form 8-K.

This information in this Item2.02 of this Form 8-K and the
Exhibit 99.1 attached hereto shall not be deemed filed for
purposes of Section18 of the Securities and Exchange Act of 1934,
as amended (the Exchange Act), or otherwise subject to the
liabilities of that Section, or incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific
reference in such a filing.

About COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS)

Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is focused on the global biosimilar market. The Company operates through developing and commercializing biosimilar products segment. Its business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial. Its long-acting granulocyte colony-stimulating factor (G-CSF) product candidate, CHS-1701, is a pegfilgrastim (Neulasta) biosimilar. Its clinical-stage pipeline consists of two anti-Tumor Necrosis Factors (anti-TNFs).

COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS) Recent Trading Information

COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS) closed its last trading session up +0.50 at 20.25 with 322,225 shares trading hands.